

## **Biography**

**Dr. Kannan Rangaramanujam** is the Arnall Patz distinguished professor of ophthalmology and co-director of center for nanomedicine at the Wilmer Eye Institute at Johns Hopkins School of Medicine. He obtained his Ph.D. in Chemical Engineering from California Institute of Technology and followed with a postdoctoral stint at the University of Minnesota (Chemistry/Chemical Engineering). His research interests are in the field of translational nanomedicine centered on a unique hydroxyl dendrimer platform technology. His team has developed approaches to target and manipulate injured glial/macrophages specifically, from systemic administration. Targeted therapies for neuroinflammation and angiogenesis are being developed with this approach, with significant implications for addressing unmet needs in many central nervous system and ocular disorders (*e.g.* childhood cerebral adrenoleukodystrophy, cerebral palsy, age-related macular degeneration, diabetic retinopathy, brain tumors, immunotherapy, neuroimaging). Dr. Rangaramanujam is an author of >15 patents (issued and pending, licensed), more than 100 peer-reviewed publications, and is supported by significant NIH and federal funding. He has won several recognitions, including fellowship of the American Institute of Medical and Biological Engineers (AIMBE) and NSF CAREER award. He is the co-founder and chief technology officer of Ashvattha Therapeutics, Orpheris Inc. and RiniSight, three spinoffs that are translating his team's patented dendrimer technologies to the clinic, with a lead product in early clinical trials for a pediatric brain disorder.

